# US Microfluidic Devices Market > US Microfluidic Devices Market Research Report: Size, Share, Trend Analysis By Applications (In Vitro Diagnostics, Drug Delivery, Point Of Care Testing, Biomedical Research), By Material Type (Polymer, Glass, Silicon, Metal), By Technology (Pressure-driven, Electrokinetic, Capillary-driven, Magnetofluidic) and By End Use (Healthcare, Pharmaceuticals, Environmental Testing, Academic Research) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.33% - **2024:** $ 1,750 Million - **2025:** $ 1,913.27 Million - **2035:** $ 4,670 Million - **Key Players:** Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Danaher Corporation (US), Fluidigm Corporation (US), Micronit Microfluidics (NL), Dolomite Microfluidics (GB), Elveflow (FR) **Report ID:** MRFR/MED/17892-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-microfluidic-devices-market-19439 --- ## Market Summary ## **US Microfluidic Devices Market Overview** As per MRFR analysis, the US Microfluidic Devices Market Size was estimated at 145.4 (USD Million) in 2023. The US Microfluidic Devices Market Industry is expected to grow from 169.54(USD Million) in 2024 to 1,000 (USD Million) by 2035. The US Microfluidic Devices Market CAGR (growth rate) is expected to be around 17.508% during the forecast period (2025 - 2035). ### **Key US Microfluidic Devices Market Trends Highlighted** The US Microfluidic Devices Market has experienced significant growth driven by advancements in technology and increasing healthcare needs. One major driver is the need for rapid diagnostics, particularly in areas such as infectious diseases and personalized medicine. The COVID-19 pandemic accelerated the demand for point-of-care testing, leading to innovations in microfluidic applications that support quick and accurate results. Regulatory support from the FDA has also played a crucial role in encouraging the development of new microfluidic devices and technologies, ensuring that they meet safety and efficacy standards. Opportunities in the US market are ripe, especially in the fields of drug delivery systems and lab-on-a-chip technologies. The increasing interest from biotechnology and pharmaceutical companies in personalized medicine presents a chance for growth and innovation within this sector. Furthermore, the integration of microfluidics with artificial intelligence and machine learning is a frontier that could enhance diagnostic capabilities and streamline workflows for healthcare providers. Recent trends indicate a shift towards miniaturization and automation in microfluidic devices, aimed at reducing costs and improving efficiency. Researchers in the US are increasingly focusing on creating adaptable and user-friendly devices that can be utilized in various settings, including home healthcare. As the shift towards telehealth and remote patient monitoring continues to evolve, there is a growing need for microfluidic devices that deliver reliable results outside traditional laboratory environments. Overall, the US Microfluidic Devices Market is poised for ongoing transformation, driven by innovation and an increasing focus on patient-centered care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Microfluidic Devices Market Drivers** ### **Rising Demand for Point-of-Care Testing** The US Microfluidic Devices Market Industry is experiencing significant growth due to the increasing demand for point-of-care testing solutions. This demand has been propelled by the need for timely diagnosis and treatment decisions in various medical conditions. According to the Centers for Disease Control and Prevention (CDC), approximately 30% of adults in the United States live with a chronic health condition, including diabetes and heart disease, which often require frequent and rapid testing. Innovations in microfluidic devices enable quick, portable, and efficient testing results, thereby improving patient outcomes. Companies like Abbott Laboratories and Thermo Fisher Scientific are investing heavily in Research and Development (R&D) to enhance their microfluidic technologies, making substantial contributions to this market driver. This growth translates to an expanding market where the value of microfluidic device revenues is anticipated to increase significantly by 2035, supporting the healthcare industry's shift toward decentralized and accessible medical testing. ### **Technological Advancements in Microfluidics** Advancements in microfluidic technologies are revolutionizing the US Microfluidic Devices Market Industry, simplifying the complexity of sample processing and analysis in healthcare. For example, the National Institutes of Health (NIH) has reported an increase in the use of microfluidic technologies in drug development, enabling high-speed screening of pharmaceutical compounds. This increase is attributed to the growing number of patents filed in the microfluidics domain, which is projected to rise by 25% in the next five years. Major players, such as Agilent Technologies, are at the forefront of these advancements, continuously enhancing the efficiency and effectiveness of microfluidic devices. Moreover, integrating artificial intelligence with microfluidics is expected to improve diagnostic accuracy and reduce operational time, further propelling market growth in the US. ### **Growing Awareness and Adoption of Personalized Medicine** The growing awareness and adoption of personalized medicine is a key driver for the US Microfluidic Devices Market Industry. Personalized medicine, which tailors treatment based on an individual’s genetic makeup, is becoming increasingly prominent. The FDA has reported a surge in regulatory approvals for personalized therapies; in the past decade, personalized medical products have seen annual growth rates of nearly 15%. Companies like Illumina, Inc.are leveraging microfluidic technologies to facilitate rapid genetic testing, thereby making personalized treatment more accessible. As more healthcare providers integrate these tailored approaches into their practice, there is a direct increase in the demand for microfluidic devices, propelling the market further. ## **US Microfluidic Devices Market Segment Insights** ### **Microfluidic Devices Market Application Insights** The Application segment of the US Microfluidic Devices Market plays a pivotal role in driving innovation and growth within the industry. The applications are diverse, encompassing in vitro diagnostics, drug delivery, point of care testing, and biomedical research. Each of these applications contributes uniquely to the market, reflecting growing needs for advanced medical technologies and diagnostics. In vitro diagnostics dominates this arena by providing efficient and rapid testing solutions, leading to better patient management and outcomes. This application holds significant relevance as it enables healthcare providers to perform tests that guide the diagnosis and treatment of numerous conditions, thereby enhancing patient care in a timely manner. Drug delivery is another critical application, as it revolutionizes the way medications are administered, leading to improved bioavailability and patient compliance. This aspect is increasingly important given the rising demand for personalized medicine, as advanced drug delivery systems can be tailored to meet individual patient needs effectively. Point of care testing further extends the reach of microfluidic technology by allowing immediate testing and results in various settings, including clinics and at home, thereby expediting critical medical decisions. This application reflects trends in decentralized healthcare and addresses a growing desire for efficient healthcare delivery. Lastly, biomedical research heavily relies on microfluidic devices to facilitate experiments and analyses, providing researchers with precise control over fluid movement and reactions at a microscale. This capability enhances experimental accuracy and enables high-throughput screening processes essential for advancing scientific knowledge. Overall, the US Microfluidic Devices Market is experiencing robust growth within this Application segment as healthcare demands evolve, emphasizing the importance of these technologies in improving patient outcomes and medical advancements. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Microfluidic Devices Market Material Type Insights** The US Microfluidic Devices Market is largely segmented by Material Type, which is crucial in defining the performance and application of these devices. The segment includes various materials such as Polymer, Glass, Silicon, and Metal, each playing a vital role in the functionality and effectiveness of microfluidic systems. Polymer is favored for its flexibility, ease of manufacturing, and cost-effectiveness, often dominating in disposable devices and prototyping. Glass provides exceptional optical clarity and chemical resistance, making it ideal for high-precision applications in diagnostics and research settings. Silicon, with its integration capabilities, serves extensively in electronic microfluidic devices, supporting advanced functionalities. Metal components enhance durability and thermal conductivity, particularly in applications requiring excellent thermal management. The growth of this market segment is driven by increasing demand for point-of-care testing, lab-on-a-chip technologies, and advancements in microfabrication techniques. Notably, the US is witnessing significant investments in Research and Development within the Microfluidic Devices Market, propelled by collaborations between universities and biotech companies, further emphasizing the importance of Material Type in driving innovation and product development within the industry. ### **Microfluidic Devices Market Technology Insights** The Technology segment of the US Microfluidic Devices Market is characterized by the diverse application of various operational principles like Pressure-driven, Electrokinetic, Capillary-driven, and Magnetofluidic methods. Pressure-driven microfluidics is widely recognized for its capability to handle multiple fluids efficiently, which has led to its extensive use in diagnostic and analytical applications. Electrokinetic methods, on the other hand, leverage electric fields to manipulate fluids at the microscale, making them suitable for applications in Lab-on-a-Chip devices and other biomedical uses. Capillary-driven systems, known for their simplicity and efficiency, rely on surface tension and are significant in point-of-care diagnostics due to their minimal power requirements. Meanwhile, Magnetofluidic techniques utilize magnetic fields to control fluid movement, enabling precise manipulations essential for advanced applications in drug delivery and targeted therapies. The integration of these technologies reflects the ongoing innovation in the field, catering to various industry needs and driving the growth of the US Microfluidic Devices Market. Overall, these approaches continue to evolve, presenting opportunities for new solutions in healthcare and analytical fields, significantly contributing to market statistics and industry advancements. ### **Microfluidic Devices Market End Use Insights** The US Microfluidic Devices Market demonstrates a diverse range of applications across various end-use sectors, including Healthcare, Pharmaceuticals, Environmental Testing, and Academic Research. The Healthcare segment plays a critical role, leveraging microfluidic technology for early diagnosis and personalized medicine, thereby improving patient outcomes. It has witnessed major advancements that enhance point-of-care testing and facilitate minimally invasive procedures. In the Pharmaceuticals sector, microfluidic devices are essential for drug development and high-throughput screening, driving efficiency in Research and Development processes. The Environmental Testing segment utilizes these devices to analyze pollutants and toxins, contributing substantially to monitoring and protecting the environment in the US, where stringent regulations are in place. Furthermore, Academic Research benefits from the applicability of microfluidics in various scientific disciplines, stimulating innovative research and discovery. These sectors collectively highlight the versatility and importance of the US Microfluidic Devices Market, reflecting the significant trends and opportunities shaping the industry landscape. As innovation continues to advance, these areas are likely to further demonstrate growth and adaptability, playing pivotal roles in addressing both current and future challenges in health, safety, and research. ## **US Microfluidic Devices Market Key Players and Competitive Insights** The US Microfluidic Devices Market is characterized by rapid technological advancements, a fiercely competitive landscape, and a wide array of applications across industries such as healthcare, pharmaceuticals, and research labs. The growing demand for precise and efficient analytical techniques has propelled a host of companies to invest heavily in research and development activities to innovate and enhance their product offerings. As a result, companies across the spectrum are vying for market share while also establishing collaborations and partnerships to leverage complementary strengths and enter new market segments. Understanding the competitive dynamics within this sector is crucial for stakeholders aiming to navigate the evolving market landscape and capitalize on emerging opportunities. Advanced MicroFabrication Equipment is a prominent player in the US Microfluidic Devices Market, leveraging its technical expertise and state-of-the-art fabrication technology. The company specializes in the production of advanced microfabrication equipment that is tailored for the development of microfluidic devices. Its strengths lie in its innovative technological solutions that focus on precision and scalability, enabling high-throughput fabrication. Advanced MicroFabrication Equipment has successfully positioned itself within the market due to its commitment to quality and efficiency, making it a trusted partner for various academic and commercial institutions looking to develop cutting-edge microfluidic solutions. The company’s robust manufacturing capabilities and industry knowledge empower it to respond swiftly to market demands and client specifications. Tecan Group is another key player in the US Microfluidic Devices Market, recognized for its comprehensive range of liquid handling and automation solutions. Tecan Group’s key products include a suite of microfluidic devices designed for applications in genomics, proteomics, and diagnostics, providing researchers with the tools necessary for high-throughput screening and process automation. The company has a strong presence in the US market, bolstered by strategic acquisitions that have expanded its product portfolio and market reach. Tecan Group's strengths include its innovative approach to product development, robust customer support, and established reputation in laboratory automation. The company continues to invest in research and development to enhance its offerings and maintain its competitive edge in the rapidly evolving microfluidics landscape. Tecan Group’s focus on creating integrated solutions that streamline workflows has positioned it favorably in the market, catering to a diverse clientele in the life sciences sector. ### **Key Companies in the US Microfluidic Devices Market Include** ## **US Microfluidic Devices Market Industry Developments** The US Microfluidic Devices Market has been witnessing significant developments recently. In October 2023, Abbott Laboratories announced an expansion of its microfluidic technology capabilities, enhancing its contributions to point-of-care diagnostics. Additionally, in September 2023, Becton Dickinson revealed a partnership with Illumina to integrate their microfluidic platforms for innovative therapies. The market has also seen steady growth, with valuations for companies like BioRad Laboratories and Thermo Fisher Scientific increasing due to heightened demand for rapid diagnostic solutions, especially in healthcare environments. Recent reports indicate that Advanced MicroFabrication Equipment has increased its market share by focusing on customized solutions tailored for specific medical applications. As for mergers and acquisitions, Fluigent acquired Microfluidics International Corporation in August 2023, marking a significant consolidation in the market. This acquisition is anticipated to bolster Fluigent’s product offerings and enhance R&D capabilities in microfluidic technologies. With the advent of new applications across various sectors, including pharmaceuticals and diagnostics, the market is poised for continued advancement, overcoming challenges and tapping into expanding opportunities in personalized medicine and device automation. ## **US Microfluidic Devices Market Segmentation Insights** ### **Microfluidic Devices Market Application Outlook** ### **Microfluidic Devices Market Material Type Outlook** ### **Microfluidic Devices Market Technology Outlook** ### **Microfluidic Devices Market End Use Outlook** ## Market Drivers ### Expansion of Point-of-Care Testing The expansion of point-of-care testing (POCT) is significantly impacting the microfluidic devices market, as these technologies enable rapid and accurate diagnostics at the site of patient care. The convenience and speed of POCT are driving its adoption in various healthcare settings, including clinics and home care. The market for POCT is projected to grow at a CAGR of approximately 15% over the next few years, reflecting the increasing demand for accessible healthcare solutions. Microfluidic devices play a pivotal role in this trend, as they allow for miniaturized testing platforms that require minimal sample volumes and provide quick results. Consequently, the microfluidic devices market is well-positioned to benefit from the ongoing shift towards decentralized healthcare and the need for timely diagnostic information. ### Rising Demand for Personalized Medicine The microfluidic devices market is experiencing a notable surge in demand driven by the increasing focus on personalized medicine. As healthcare shifts towards tailored treatments, microfluidic technologies enable precise drug delivery and diagnostics. This market segment is projected to grow at a CAGR of approximately 20% over the next five years. The ability to conduct multiple tests simultaneously on a single platform enhances efficiency and reduces costs, making microfluidic devices essential in clinical settings. Furthermore, advancements in biomarker discovery and genetic testing are likely to propel the adoption of these devices, as they facilitate rapid and accurate patient-specific solutions. Consequently, the microfluidic devices market is poised for substantial growth as healthcare providers seek innovative ways to improve patient outcomes through personalized approaches. ### Technological Advancements in Microfluidics Technological innovations are significantly influencing the microfluidic devices market, enhancing their capabilities and applications. Recent developments in materials science, such as the use of polymers and nanomaterials, have improved the performance and reliability of microfluidic devices. These advancements allow for more complex fluid manipulations and integration with electronic systems, which is crucial for applications in diagnostics and drug delivery. The market is expected to reach a valuation of over $10 billion by 2026, driven by these technological enhancements. Moreover, the integration of artificial intelligence and machine learning into microfluidic systems is likely to optimize processes and improve data analysis, further expanding the market's potential. As a result, the microfluidic devices market is becoming increasingly sophisticated, catering to diverse applications across various sectors. ### Growing Investment in Research and Development Investment in research and development (R&D) is a critical driver for the microfluidic devices market, as it fosters innovation and the introduction of new products. Increased funding from both public and private sectors is facilitating the exploration of novel applications, particularly in the fields of diagnostics and therapeutics. In the US, federal grants and venture capital investments are supporting startups and established companies alike, leading to breakthroughs in microfluidic technology. This influx of capital is expected to enhance the market's growth trajectory, with projections indicating a compound annual growth rate of around 18% through 2027. As R&D efforts continue to expand, the microfluidic devices market is likely to witness the emergence of cutting-edge solutions that address unmet medical needs and improve healthcare delivery. ### Regulatory Support and Standardization Efforts Regulatory support and standardization efforts are emerging as vital drivers for the microfluidic devices market, as they enhance product reliability and consumer confidence. Regulatory bodies in the US are increasingly recognizing the potential of microfluidic technologies, leading to streamlined approval processes for innovative devices. This supportive environment encourages manufacturers to invest in the development of new products, knowing that they can navigate regulatory hurdles more efficiently. Additionally, standardization initiatives are being established to ensure quality and interoperability among devices, which is crucial for widespread adoption. As a result, the microfluidic devices market is likely to experience accelerated growth, with a projected increase in market size driven by the assurance of safety and efficacy in new technologies. ## Future Outlook The [Microfluidic Devices Market](https://www.marketresearchfuture.com/reports/microfluidic-devices-market-954) is projected to grow at a 9.33% CAGR from 2025 to 2035, driven by advancements in diagnostics, drug delivery, and lab-on-a-chip technologies. **New opportunities:** - Development of portable diagnostic devices for remote healthcare settings. - - Integration of AI for enhanced data analysis in microfluidic applications. - Expansion into personalized medicine through tailored microfluidic solutions. By 2035, the microfluidic devices market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: In Vitro Diagnostics (Largest) vs. Point Of Care Testing (Fastest-Growing) The market share distribution among the application values showcases the predominance of In Vitro Diagnostics, which holds a significant portion of the overall US microfluidic devices market. Following this, the Point Of Care Testing segment is rapidly gaining ground, demonstrating substantial interest from healthcare providers looking for immediate diagnostic solutions. Drug Delivery and Biomedical Research, while important, represent smaller shares compared to these leading applications. Growth trends in the application segment are heavily influenced by advancements in technology and increasing demand for rapid, accurate diagnostic methods. In Vitro Diagnostics is benefiting from ongoing innovations that improve testing accuracy, while Point Of Care Testing is propelled by the necessity for quick results in clinical settings. Additionally, the pandemic has accelerated the need for accessible diagnostic tools, with potential for sustained growth in both segments. In Vitro Diagnostics (Dominant) vs. Drug Delivery (Emerging) In Vitro Diagnostics is recognized as the dominant player within the US microfluidic devices market, characterized by its widespread use in clinical laboratories and hospitals for accurate disease diagnosis. This segment offers a variety of testing options that cater to diverse health issues, ensuring its strong market presence. Conversely, Drug Delivery is emerging as a noteworthy segment, gaining traction due to innovations in microfluidic technologies that enhance drug absorption and targeted delivery. As the healthcare landscape evolves, these segments reflect distinct characteristics, with In Vitro Diagnostics focusing on diagnostic precision, while Drug Delivery emphasizes therapeutic efficacy and patient compliance through advanced delivery systems. ### By Material Type: Polymer (Largest) vs. Glass (Fastest-Growing) In the US [microfluidic devices market](https://www.marketresearchfuture.com/reports/microfluidic-devices-market-954), the material type segment is characterized by a diverse array of materials that cater to a variety of applications. Polymer leads the market with a significant share due to its versatility, cost-effectiveness, and ease of fabrication. Glass, while currently smaller in market share, is gaining traction because of its superior chemical resistance and optical clarity, making it suitable for advanced applications. Growth trends within this segment are heavily influenced by advancements in technology and increasing demand for miniaturized diagnostic devices. The polymer segment benefits from innovations in material science that enhance performance, while glass is experiencing a surge due to its use in high-precision laboratory equipment. Overall, both segments are expected to see robust growth driven by an expanding application base and technological developments. Polymer (Dominant) vs. Glass (Emerging) The polymer segment is established as the dominant player in the market due to its widespread use in various microfluidic applications, including diagnostics and drug delivery systems. Polymers offer advantages such as flexibility, lower production costs, and compatibility with a variety of surface modifications, making them favored for high-throughput scenarios. On the other hand, the glass segment is emerging, noted for its superior durability and precision. Glass microfluidic devices are often preferred in applications that require high stability and reproducibility, particularly in the life sciences and pharmaceutical sectors. The contrasting characteristics of these materials serve diverse market needs, positioning them uniquely within the US microfluidic devices market. ### By Technology: Pressure-driven (Largest) vs. Electrokinetic (Fastest-Growing) In the US microfluidic devices market, the market share is prominently distributed among various technologies, with pressure-driven systems taking the lead. This segment has established dominance due to its reliability and effectiveness in a wide array of applications. Electrokinetic technology, on the other hand, is witnessing rapid growth, appealing to innovators seeking efficient solutions for miniaturization and enhanced control in fluid dynamics. The growth trends in this segment are primarily propelled by advancements in the medical and diagnostics fields, where the demand for precise and efficient fluid manipulation is increasing. Moreover, increasing investments in research and development are likely to bolster innovation in electrokinetic systems, further enhancing their adoption. As the market evolves, these trends suggest a dynamic shift towards integrating new technologies that improve functionality and efficacy. Technology: Pressure-driven (Dominant) vs. Electrokinetic (Emerging) The pressure-driven technology in the microfluidics arena is characterized by its established presence and reliable operational capabilities, making it the dominant force in the market. It is often preferred for its ease of use and versatility across a range of applications, especially in laboratory settings. Conversely, electrokinetic technology is seen as an emerging player that harnesses electric fields to manipulate fluids at micro and nano scales. Its fast growth can be attributed to ongoing innovations that offer extensive benefits in precision and efficiency, especially in applications like point-of-care testing and drug delivery systems. As the competitive landscape evolves, these two technologies will continue to influence each other, reshaping the future of microfluidics. ### By End-use: Healthcare (Largest) vs. Pharmaceuticals (Fastest-Growing) In the US microfluidic devices market, Healthcare dominates with a substantial share, driven by the increasing demand for precise and efficient diagnostics. Pharmaceuticals, while not as large as Healthcare, is experiencing rapid growth due to the rising need for advanced drug delivery systems and personalized medicine. Environmental Testing and Academic Research also play significant roles, yet their market shares remain comparatively smaller. Recent trends indicate that the Healthcare segment will continue to lead, fueled by technological innovations and a push for improved disease management. The Pharmaceuticals sector is projected to grow swiftly as biopharmaceutical companies adopt microfluidic technologies for drug formulation and testing, thus catering to an evolving market landscape that prioritizes rapid and reliable results. Healthcare (Dominant) vs. Pharmaceuticals (Emerging) The Healthcare segment stands out as the dominant force in the US microfluidic devices market, characterized by its broad applications in diagnostics, such as blood analysis and pathogen detection. This segment benefits from extensive investment in healthcare infrastructures and a shift towards point-of-care testing, allowing for immediate results and better patient outcomes. In contrast, the Pharmaceuticals segment is emerging as a key player, with increasing investments in R&D leading to the development of innovative drug delivery systems. This segment thrives on the need for more efficient drug testing protocols and personalized treatments, making it a vital area of focus for biopharmaceutical companies looking to enhance therapeutic effectiveness. ## Competitive Benchmarking The microfluidic devices market is characterized by a dynamic competitive landscape, driven by innovation, technological advancements, and strategic partnerships. Key players such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Agilent Technologies (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Abbott Laboratories (US) emphasizes strategic acquisitions to bolster its capabilities in diagnostics. Agilent Technologies (US) is leveraging its expertise in analytical instrumentation to integrate microfluidic technologies, thereby enhancing its competitive edge. Collectively, these strategies contribute to a robust competitive environment, fostering growth and innovation within the market.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger corporations leverage their resources to capture significant market shares. The collective influence of these key players shapes the competitive dynamics, as they vie for leadership through innovation and strategic positioning. In October Thermo Fisher Scientific (US) announced the launch of a new microfluidic platform designed to streamline genomic analysis. This strategic move is significant as it not only enhances their product offerings but also positions them to meet the growing demand for rapid and accurate genomic testing. The introduction of this platform is likely to strengthen their foothold in the diagnostics sector, aligning with current trends towards personalized medicine. In September Abbott Laboratories (US) completed the acquisition of a microfluidics startup specializing in point-of-care testing technologies. This acquisition is pivotal as it expands Abbott's capabilities in the rapidly evolving diagnostics market, allowing for the integration of advanced microfluidic solutions into their existing product lines. Such strategic actions indicate a clear focus on enhancing their technological prowess and market reach. In August Agilent Technologies (US) entered into a partnership with a leading biotechnology firm to co-develop next-generation microfluidic devices. This collaboration is indicative of Agilent's commitment to innovation and its strategy to leverage external expertise to accelerate product development. By aligning with a biotechnology leader, Agilent is likely to enhance its competitive positioning and drive advancements in microfluidic applications. As of November current competitive trends in the microfluidic devices market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise for enhanced innovation. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technological advancements and supply chain reliability, rather than solely on price. This shift underscores the importance of innovation and adaptability in maintaining a competitive edge in the market. ## Recent News & Developments The US Microfluidic Devices Market has been witnessing significant developments recently. In October 2023, Abbott Laboratories announced an expansion of its microfluidic technology capabilities, enhancing its contributions to point-of-care diagnostics. Additionally, in September 2023, Becton Dickinson revealed a partnership with Illumina to integrate their microfluidic platforms for innovative therapies. The market has also seen steady growth, with valuations for companies like BioRad Laboratories and Thermo Fisher Scientific increasing due to heightened demand for rapid diagnostic solutions, especially in healthcare environments. Recent reports indicate that Advanced MicroFabrication Equipment has increased its market share by focusing on customized solutions tailored for specific medical applications. As for mergers and acquisitions, Fluigent acquired Microfluidics International Corporation in August 2023, marking a significant consolidation in the market. This acquisition is anticipated to bolster Fluigent’s product offerings and enhance R&D capabilities in microfluidic technologies. With the advent of new applications across various sectors, including pharmaceuticals and diagnostics, the market is poised for continued advancement, overcoming challenges and tapping into expanding opportunities in personalized medicine and device automation. ## Report Scope | MARKET SIZE 2024 | 1750.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1913.27(USD Million) | | MARKET SIZE 2035 | 4670.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.33% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Danaher Corporation (US), Fluidigm Corporation (US), Micronit Microfluidics (NL), Dolomite Microfluidics (GB), Elveflow (FR) | | Segments Covered | Application, Material Type, Technology, End-use | | Key Market Opportunities | Advancements in point-of-care diagnostics drive growth in the microfluidic devices market. | | Key Market Dynamics | Technological advancements drive innovation in microfluidic devices, enhancing diagnostic capabilities and expanding application areas. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the projected market valuation for the US microfluidic devices market by 2035?** A: The projected market valuation for the US microfluidic devices market is $4670.0 Million by 2035. **Q: What was the market valuation of the US microfluidic devices market in 2024?** A: The market valuation of the US microfluidic devices market was $1750.0 Million in 2024. **Q: What is the expected CAGR for the US microfluidic devices market during the forecast period 2025 - 2035?** A: The expected CAGR for the US microfluidic devices market during the forecast period 2025 - 2035 is 9.33%. **Q: Which application segment is projected to have the highest valuation in the US microfluidic devices market by 2035?** A: The In Vitro Diagnostics application segment is projected to have the highest valuation, reaching $1800.0 Million by 2035. **Q: What are the key players in the US microfluidic devices market?** A: Key players in the US microfluidic devices market include Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies. **Q: Which material type is expected to dominate the US microfluidic devices market by 2035?** A: The Polymer material type is expected to dominate the US microfluidic devices market, with a projected valuation of $1800.0 Million by 2035. **Q: What is the projected valuation for the Point Of Care Testing segment by 2035?** A: The projected valuation for the Point Of Care Testing segment in the US microfluidic devices market is $1200.0 Million by 2035. **Q: How does the market valuation for the Drug Delivery segment compare to the Biomedical Research segment by 2035?** A: By 2035, the Drug Delivery segment is projected to reach $1000.0 Million, while the Biomedical Research segment is expected to reach $670.0 Million. **Q: What technology segment is anticipated to show significant growth in the US microfluidic devices market?** A: The Electrokinetic technology segment is anticipated to show significant growth, with a projected valuation of $1100.0 Million by 2035. **Q: Which end-use segment is expected to have the lowest valuation in the US microfluidic devices market by 2035?** A: The Academic Research end-use segment is expected to have the lowest valuation, projected at $570.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-microfluidic-devices-market-19439*